Dr. Smith is dedicated to early detection and treatment of disease and using this knowledge to advance the state of medicine and the economy. He is a passionate mover for the commercialization of the products of research, and has started nine companies with a present value of $300 million. In 2013, he retired from NRC to help build a spin-off company, Innovative Biodiagnostics, specializing in tests for colon cancer and breast cancer.